BRPI0417406A - anticorpo do receptor anti-igf-i - Google Patents

anticorpo do receptor anti-igf-i

Info

Publication number
BRPI0417406A
BRPI0417406A BRPI0417406-2A BRPI0417406A BRPI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A BR PI0417406 A BRPI0417406 A BR PI0417406A
Authority
BR
Brazil
Prior art keywords
igf
antibodies
receptor
cancer
derivatized
Prior art date
Application number
BRPI0417406-2A
Other languages
English (en)
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of BRPI0417406A publication Critical patent/BRPI0417406A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

"ANTICORPO DO RECEPTOR ANTI-IGF-I". A presente invenção refere-se a anticorpos, anticorpos humanizados, anticorpos recondicionados, fragmentos de anticorpo, anticorpos derivatizados e conjugados dos mesmos com agente citotóxicos, que especificamente se ligam ao receptor do fator-I de crescimento equivalente à insulina e o inibem, antagonizam os efeitos de IGF-I, IGF-II e soro sobre o crescimento e sobrevivência de células de tumor e que são substancialmente destituídos de atividade agonista. Os ditos anticorpos e fragmentos destes podem ser usado, opcionalmente em conjunção com outros agentes terapêuticos, no tratamento de tumores que expressam níveis elevados de receptor de IGF-I, tais como câncer de mama, câncer de cólon, câncer pulmonar, carcinoma ovariano, sarcoma sinovial, câncer da próstata e câncer pancreático e os ditos anticorpos derivatizados podem ser usados na diagnose e formação de imagem de tumores que expressem níveis elevados de receptor de IGF-I.
BRPI0417406-2A 2003-12-08 2004-12-07 anticorpo do receptor anti-igf-i BRPI0417406A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
BRPI0417406A true BRPI0417406A (pt) 2007-04-03

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417406-2A BRPI0417406A (pt) 2003-12-08 2004-12-07 anticorpo do receptor anti-igf-i

Country Status (13)

Country Link
EP (1) EP1692176A4 (pt)
JP (1) JP2008502589A (pt)
KR (1) KR20070001883A (pt)
CN (1) CN1886424A (pt)
AU (1) AU2004303792A1 (pt)
BR (1) BRPI0417406A (pt)
CA (1) CA2548065A1 (pt)
CR (1) CR8426A (pt)
EA (1) EA009807B1 (pt)
EC (1) ECSP066595A (pt)
IL (1) IL174770A0 (pt)
MX (1) MXPA06005540A (pt)
NO (1) NO20063155L (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
KR20130065665A (ko) * 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital NEW ASPARAGINASE AND METHOD FOR THE TREATMENT OF DISEASES RELATED TO ASPARAGINE DEPENDENCE
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
CN110691794B (zh) * 2017-05-30 2023-10-27 帝人制药株式会社 抗igf-i受体抗体
CN118615438A (zh) * 2023-03-07 2024-09-10 康方药业有限公司 包含抗ctla4-抗pd-1双特异性抗体的药物组合及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
EP2796468A2 (en) * 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Also Published As

Publication number Publication date
IL174770A0 (en) 2006-08-20
EP1692176A4 (en) 2008-11-12
EP1692176A1 (en) 2006-08-23
JP2008502589A (ja) 2008-01-31
CA2548065A1 (en) 2005-07-07
MXPA06005540A (es) 2006-08-17
EA200600931A1 (ru) 2006-10-27
AU2004303792A1 (en) 2005-07-07
CR8426A (es) 2007-12-04
EA009807B1 (ru) 2008-04-28
NO20063155L (no) 2006-08-11
KR20070001883A (ko) 2007-01-04
CN1886424A (zh) 2006-12-27
ECSP066595A (es) 2006-10-17

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
Clausen et al. Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility
Gan et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy
Rose et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer
Prendergast et al. Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity
Rojo et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study
MY157757A (en) Antagonist antibody against epha2 for the treatment of cancer
Pupa et al. Regulation of breast cancer response to chemotherapy by fibulin-1
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
Chia et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
Palacino et al. ORM-5029: a first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer
Luca et al. Peptide ligands specifically targeting HER2 Receptor and the role played by a synthetic model system of the receptor extracellular domain: Hypothesized future perspectives
Olson et al. HER2-selective and reversible tyrosine kinase inhibitor tucatinib potentiates the activity of T-DM1 in preclinical models of HER2-positive breast cancer
Abu-Yousif et al. Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts
BRPI0417406A (pt) anticorpo do receptor anti-igf-i
Zhou et al. Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer
Kareem et al. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
Shi et al. Antibody-drug conjugates in breast cancer: advances and prospects
Fabian Tamoxifen: will less equal more in women with precancerous breast disease?
Bello Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer
Hillairet de Boisferon et al. Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
Nilsson et al. Different toxicity profiles for drug-versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model
Lee et al. Abstract# 1954: Tumor suppression through p53-mediated Galectin-3 secretion and apoptosis induction

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: IMMUNOGEN, INC. (US)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.